D&D Pharmatech said on the 18th that its U.S. affiliate G-Alpha Therapeutics (G-Alpha) has officially launched. G-Alpha develops alpha radiopharmaceutical therapies. Alpha radiopharmaceutical therapies destroy cancer cells with strong energy while minimizing exposure of normal cells to radiation.
G-Alpha's chief executive officer (CEO) is Dr. Kevin Bunker, co-founder of the Nasdaq-listed company Jentaris. Dr. Peter Hwang, formerly of the global pharmaceutical company Zai Lab, is the chief scientific officer (CSO), and Dr. Colin Hayward, formerly of the global radiopharmaceutical company Telix, is the chief medical officer (CMO).
D&D Pharmatech is the third-largest shareholder with a 15% equity stake in G-Alpha. In addition, the healthcare investment firms OrbiMed and Tybourne Capital are the largest shareholders of G-Alpha. The G-Alpha board includes D&D Pharmatech CEO Lee Seulgi and OrbiMed executives.